Certolizumab pegol for the treatment of psoriatic arthritis.

about

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy Secukinumab (AIN-457) for the treatment of Psoriasis.Leukocytoclastic vasculitis drug reaction to certolizumab pegol.

P2860

Q28074393-8F58A84B-451E-4CF1-846D-C0A23A52FF76 Q38662868-AEAA41C4-53A1-4243-9012-43D2E3E94F90 Q42053842-264E167A-81CF-4465-9A0B-D2CF92E6B6C9

P2860

Certolizumab pegol for the treatment of psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q38344194

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Certolizumab pegol for the treatment of psoriatic arthritis.

@en

type

Item

label

Certolizumab pegol for the treatment of psoriatic arthritis.

@en

prefLabel

Certolizumab pegol for the treatment of psoriatic arthritis.

@en

P1476

Certolizumab pegol for the treatment of psoriatic arthritis.

@en

P2093

Arthur Kavanaugh

http://www.w3.org/2001/XMLSchema#string

Renata Baronaite Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Certolizumab pegol

Certolizumab pegol for the treatment of Crohn's disease

Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study

Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review.

P304

307-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/1744666X.2015.1009897

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25651776

http://www.w3.org/2001/XMLSchema#string

Certolizumab pegol for the treatment of psoriatic arthritis.

about

P2860

P2860

Certolizumab pegol for the treatment of psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698